DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-036/S-008

GlaxoSmithKline
Attn: Sherman N. Alfors, US Regulatory Affairs
PO Box 13398
Five Moore Drive
Research Triangle Park, NC 27709

Dear Mr. Alfors:

Please refer to your supplemental new drug application dated November 4, 2005, received November 4, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for RELENZA® (zanamivir for inhalation).

We acknowledge receipt of your submissions dated:

November 21, 2005	February 7, 2006	March 7, 2006
December 2, 2005	February 22, 2006	March 14, 2006
January 18, 2006	March 1, 2006	March 21, 2006
January 26, 2006	March 2, 2006	March 26, 2006
		March 27, 2006

This supplemental new drug application provides for the use of RELENZA® (zanamivir for inhalation) for prophylaxis of influenza in adults and children five years of age and older.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert and text for the patient package insert).

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 21-036/S-008**." Approval of this submission by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric subjects unless this requirement is waived or deferred. We are waiving the pediatric study requirement for this application for subjects less than five years of age.

We remind you of your postmarketing study commitments in your submission dated March 26, 2006. These commitments are listed below.

1. Provide an annual update on emergence of resistance to zanamivir, as well as cross-resistance between zanamivir and other neuraminidase inhibitors, as an integrated review of information from NISN (Neuraminidase Inhibitor Surveillance Network), data collected by GlaxoSmithKline (GSK), and information in the published literature. Each annual update will include information on the methodologies (e.g., culture, PCR) used in studies during that reporting period. Timeline: GSK will provide this annual update as part of the NDA Annual Reports due within 60 days of the original approval anniversaries in July 2007, July 2008, and July 2009.

2. Submit a postmarketing adverse drug experience report to Division of Antiviral Products (DAVP) as a "15-Day Alert Report" for each of the following serious adverse events:
    a. anaphylaxis
    b. bronchospasm or other pulmonary adverse event
    c. cardiovascular adverse event
    d. any adverse event with a fatal outcome

    Consistent with 21 CFR 314.80, GSK will make diligent efforts to obtain as complete a set of information as possible, including information about antecedent and concomitant medical circumstances of the adverse experience or fatality, results of laboratory tests, a copy of any available medical records, and a copy of the autopsy report (if performed). A "15-Day Alert Report - Follow Up" will be submitted to DAVP if additional information is obtained after the deadline for submission of the initial report. The 15-Day Alert Reports due to DAVP each week will be collected and submitted as a batch, once a week, to DAVP. Each such submission will be sent to NDA 21-036 as "General Correspondence: Safety Reports per Postmarketing Commitment". Timeline: Such Alert Reports will be prepared and submitted by GSK for the specified events occurring through May 31, 2009.

3. Prepare a Wall Chart for medical practices and pharmacies on how to use the Relenza Diskhaler. This Wall Chart will be an illustration-intensive (not text intensive) aid to patient education. Versions will be prepared in English and Spanish. Timeline: GSK will submit the proposed Wall Chart and distribution plan/timeline to DAVP for review and comment no later than June 30, 2006.

4. Meet with investigators at NIAID to develop a Concept Protocol and seek funding to assess the effects of zanamivir 10mg inhaled once daily for 2 months on clinical laboratory measures of safety. Timeline: GSK will meet with NIAID by July 31, 2006 and provide DAVP with meeting minutes including the outcome of the meeting by August 31, 2006.

Submit clinical protocols to your IND for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all study final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii), you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies, number of patients entered into each study. All submissions, including supplements, relating to these postmarketing study commitments must be prominently labeled

"**Postmarketing Study Commitment Protocol**", "**Postmarketing Study Commitment Final Report**", or "**Postmarketing Study Commitment Correspondence**."

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
WO 22, Room 4447
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call David Araojo, Pharm.D., Regulatory Project Manager, at (301) 796-0669.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, M.D.
Director
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure: approved draft labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Debra Birnkrant
3/29/2006 10:47:17 AM
NDA 21-036